Editor

Itzik Elbaz, Co-Founder and Co-CEO of Artlist

Artlist Empowers the Future of Creativity with Groundbreaking AI Voiceover Integration

Artlist, the forefront creative technology company renowned for its expansive collection of royalty-free digital assets, unveils a pioneering enhancement to its platform: an innovative AI voiceover generator. This breakthrough feature positions Artlist as the first creative asset platform to integrate such advanced capabilities directly into its suite of tools. The AI voiceover generator, now available…

Read More

OCON Therapeutics Secures $10M to Revolutionize Women’s Health with Advanced Drug Delivery Solutions

OCON Therapeutics, a pioneer recognized by the World Economic Forum for its advancements in drug delivery, has announced a significant milestone with the completion of a $10 million investment round led by RH Capital. This funding marks a pivotal moment for OCON as it accelerates efforts to redefine the standard of care in women’s health…

Read More

Better Juice Unveils Breakthrough in Sugar Reduction for Sorbets and Fruit Ice Creams

Better Juice, Ltd., a pioneering foodTech company, has introduced a game-changing innovation aimed at revolutionizing the sorbet and fruit ice cream market. Leveraging their advanced enzymatic technology, Better Juice has successfully reduced the sugar content in fruit sorbets by up to 70%, offering health-conscious consumers a guilt-free option for indulgence. The launch marks a significant…

Read More

RXO to Acquire Coyote Logistics from UPS, Cementing Position as a Leader in North American Transportation

In a strategic move to bolster its presence in the North American transportation sector, RXO (NYSE: RXO) has announced its definitive agreement to acquire Coyote Logistics from UPS for $1.025 billion in cash. This acquisition is set to propel RXO to the forefront as the third-largest provider of brokered transportation in the region, significantly enhancing…

Read More

Vico Therapeutics Secures €65.8 Million in Series B Funding to Advance Groundbreaking Neurological Therapies

Vico Therapeutics, a pioneering clinical-stage genetic medicines company, has successfully closed its Series B funding round with a total investment of €65.8 million ($70.7 million). This financing round, led by Seroba and Kurma Partners, marks a significant milestone in Vico’s journey towards developing transformative therapies for severe neurological diseases. Vico Therapeutics specializes in antisense oligonucleotide…

Read More

VoltR Secures €4 Million to Revolutionize Battery Sustainability in Europe

VoltR Advances Sustainable Lithium Battery Manufacturing with €4 Million Seed Funding VoltR, a pioneering French deep-tech company specializing in sustainable lithium batteries, has successfully raised €4 million in seed funding to scale its innovative processes. The funding round, led by prominent investors including C4 Ventures, Exergon, Pays de la Loire Participations, and Anjou Amorçage, marks…

Read More

Valneva’s Breakthrough: Canada Approves World’s First Chikungunya Vaccine

Valneva SE has achieved a historic milestone with Health Canada’s approval of the world’s first chikungunya vaccine. Following its successful launch in the U.S. and pending European authorization, this decision underscores IXCHIQ®’s pivotal role in global healthcare strategy. Chikungunya, a mosquito-borne virus causing severe joint pain and fever, poses a significant public health threat with…

Read More

mika Secures €800k to Revolutionize SME Accounting with AI Innovation

In a groundbreaking move for the tech startup scene, Berlin-based mika has successfully raised €800k in pre-seed funding to bolster its mission of simplifying accounting and tax obligations for small and medium enterprises (SMEs). Led by the strategic alliance Samen Slimmer, comprising Keen Venture Partners, DFF, and Slimmer AI, this investment marks a pivotal moment…

Read More

Ethris GmbH: Leading the Charge in mRNA-Based Therapeutics with $5 Million Investment

Since its inception, Ethris GmbH has been a trailblazer in mRNA technology, revolutionizing the biotech landscape with its innovative approach to respiratory and cardiovascular diseases. Founded on a vision of harnessing messenger RNA (mRNA) for therapeutic breakthroughs, Ethris has consistently pushed boundaries, drawing attention from investors and global biotech leaders alike. Breakthroughs and Strategic Growth…

Read More